Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs

Methods in Molecular Biology

Volumn 480, Issue , 2009, Pages 65-83

  Zhang, Chuanbo ^a   Newsome, Joseph T ^a   Mewani, Rajshree ^a   Pei, Jin ^a   Gokhale, Prafulla C ^a   Kasid, Usha N ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antisense oligonucleotide; Cationic liposomes; Dimyristoyl 1,2 diacyl 3 trimethylammonium propane (DMTAP); Ionizing radiation; Pharmacokinetics and biodistribution; Prostate cancer; Raf 1; SiRNA; Systemic delivery; Toxicology

Indexed keywords

MUS; MUS MUSCULUS;

EID: 84934435712     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-429-2_5     Document Type: Article

References (29)

1. Kasid, U., Pfeifer, A., Brennan, T., Beckett, M., Weichselbaum, R.R., Dritschilo, A., and Mark, G.E. (1989) Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243, 1354-1356.
2. Soldatenkov, V.A., Dritschilo, A., Wang, F-H., Olah, Z., Anderson, W.B., and Kasid, U. (1997) Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Can. J. Sci. Am. 3, 13-20.
3. Iorns, E., Lord, C.J., Turner, N., and Ashworth, A. (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6, 556-568.
4. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M., and Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 6, 668-675.
5. Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajiala, L., Saxinger, C., and Zhang, R. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 94, 2620-2625.
6. Marshall, J.L., Eisenberg, S.G., Johnson, M.D., Hanfelt, J., Dorr, F.A., El-Ashry, D., Oberst, M., Fuxman, Y., Holmlund, J., and Malik, S. (2004) A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 4, 268-274.
7. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Röhl, I., Toudjarska, I.., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., and Vornlocher, H.P. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178.
8. Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C.S., Jeffs, L.B., Judge, A., MacLachlan, I.., and Polisky, B. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007.
9. Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., and Stoffel, M. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
10. Baigude, H., McCarroll, J., Yang, C.S., Swain, P.M., and Rana, T.M. (2007) Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 24, 237-241.
11. Gokhale, P.C., Soldatenkov, V., Wang, F-H., Rahman, A., Dritschilo, A., and Kasid, U.(1997) Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression, in vitro and in vivo: implications for gene therapy of radioresistant cancer. Gene Ther. 4, 1289-1299.
12. Gokhale, P.C., McRae, D., Monia, B.P., Bagg, A., Rahman, A., Dritschilo, A., and Kasid, U. (1999) Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev. 9, 191-201.
13. Gokhale, P.C., Zhang, C., Newsome, J., Pei, J., Ahmad, I., Rahman, A., Dritschilo, A., and Kasid, U. (2002) Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome (LErafAON). Clin. Cancer Res. 8, 3611-3621.
14. Mewani, R.R., Tang, W., Rahman, A., Dritschilo, A., Ahmad, I., Kasid, U.N., and Gokhale, P.C. (2004) Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int. J. Oncol. 24, 1181-1188.
15. Pei, J., Zhang, C., Gokhale, P.C., Rahman, A., Dritschilo, A., Ahmad, I., and Kasid, U. (2004) Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel, and gemcitabine. Anticancer Drugs 15, 243-253.
16. Pal, A., Ahmad, A., Khan, S., Sakabe, I., Zhang, C., Kasid, U., and Ahmad, I. (2005) Systemic delivery of RafsiRNA using cationic cardiolipin liposome silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol. 26, 1087-1091.
17. Zhang, C., Pei, J., Kumar, D., Sakabe, I., Boudreau, H.E., Gokhale, P.C., and Kasid, U.N. (2007) Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. In: Target Discovery and Validation Reviews and Protocols, Vol. 2, Emerging Molecular Targets and Treatment Options (Sioud, M., ed). Humana Press, Inc. Methods Mol. Biol. 361, pp 163-185.
18. Heidel, J.D., Yu, Z., Liu, J.Y., Rele, S.M., Liang, Y., Zeidan, R.K., Kornbrust, D.J., and Davis, M.E. (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715-5721.
19. Pirollo, K.P., Rait, A., Zhou, Q., Hwang, S.H., Dagata, J.A., Zon, G., Hogrefe, R.I., Palchik, G., and Chang, E.H. (2007) Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67, 2938-2943.
20. Palliser, D., Chowdhury, D., Wang, Q.Y., Lee, S.J., Bronson, R.T., Knipe, D.M., and Lieberman, J. (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89-94
21. Kasid, U. and Dritschilo, A. (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22, 5876-5884.
22. Kasid, U., Suy, S., Dent, P., Ray, S., Whiteside, T.L., and Sturgill, T.W. (1996) Activation of Raf by ionizing radiation. Nature 382, 813-816.
23. Suy, S., Anderson, W.B., Dent, P., Chang, E., and Kasid, U. (1997) Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene 15, 53-61.
24. Rudin, C.M., Holmlund, J., Fleming, G.F., Mani, S., Stadler, W.M., Schumm, P., Monia, B.P., Johnston, J.F., Geary, R., Yu, R.Z., Kwoh, T.J., Dorr, F.A., and Ratain, M.J. (2001) Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7, 1214-1220.
25. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844.
26. Rudin, C.M., Marshall, J.L., Huang, C.H., Kindler, H.L., Zhang, C., Kumar, D., Gokhale, P.C., Steinberg, J., Wanaski, S., Kasid, U.N., and Ratain, M.J. (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res. 10, 7244-7251.
27. Dritschilo, A., Huang, C.H., Rudin, C.M., Marshall, J., Collins, B., Dul, J.L., Zhang, C., Kumar, D., Gokhale, P.C., Ahmad, A., Ahmad, I., Sherman, J.W., and Kasid, U.N. (2006) Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 12, 1251-1259.
28. Boudreau, H.E., Broustas, C.G., Gokhale, P.C., Kumar, D., Mewani, R.R., Rone, J.D., Haddad, B.R., and Kasid, U. (2007) Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation. Int. J. Mol. Med. 19, 29-39.
29. Gibaldi, M. and Perrier, D. (1982) Pharmacokinetics, 2nd edition, Marcel Dekker, New York, pp 45-111.